Company intelligence / Profile preview

Swissfillon

Visp, Valais, Switzerland

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Swissfillon was a Switzerland-based drug product-focused CDMO specializing in sterile fill-finish manufacturing for complex pharmaceuticals. The company provided aseptic filling and related development services for injectable products in prefilled syringes, cartridges, and vials, supporting both clinical-stage and early commercial programs. Founded in 2013 in Visp, Swissfillon was approved by Swissmedic for the European market and by the FDA for the U.S. market. In October 2021, it was acquired by ten23 health, and the Visp filling operation was subsequently rebranded under the ten23 health name.

Modalities: BiologicSmall molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Swissfillon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swissfillon.

Explore the full profile